Upstream Bio NASDAQ:UPB At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.

Location: Waltham, Massachusetts, United States | Website: https://upstreambio.com/ | Industry: Pharmaceutical and Manufacturing | Sector: Manufacturing